Freenome Holdings, Inc. (FRNM)

Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.

While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the healthcare industry in the United States and other developed countries. The Company is led by Chairman Joseph Edelman, Chief Executive Officer Adam Stone, Chief Business Officer Michael Altman and Chief Financial Officer Sam Cohn.